Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

VEGFR (vascular endothelial growth factor receptor) targeting cracking peptide conjugate and application thereof

A conjugated and targeted technology, applied in the field of bioengineering, can solve the problems of unreported cleavage peptide combined with anti-VEGFRACE treatment research and other problems, and achieve the effect of increasing killing effect, increasing selectivity and inhibiting signaling pathway.

Active Publication Date: 2022-03-22
XIEHE HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI & TECH UNIV
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the current clinical TACE technology is mainly based on the chemotherapeutic drug doxorubicin, and there has been no report on the use of lytic peptides combined with anti-VEGFR for TACE treatment research

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • VEGFR (vascular endothelial growth factor receptor) targeting cracking peptide conjugate and application thereof
  • VEGFR (vascular endothelial growth factor receptor) targeting cracking peptide conjugate and application thereof
  • VEGFR (vascular endothelial growth factor receptor) targeting cracking peptide conjugate and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0024] The principles and features of the present invention are described below in conjunction with the accompanying drawings, and the examples given are only used to explain the present invention, and are not intended to limit the scope of the present invention.

[0025] 1. Design of cleavage peptide-polypeptide conjugates targeting VEGFR

[0026] The present invention adopts the coupling of VEGFR polypeptide ligand and cleavage peptide to form bifunctional polypeptide drug, such as figure 1 As shown, we selected the previously reported VEGFR polypeptide ligand (polypeptide sequence: glutamine-lysine-arginine-lysine-arginine-lysine-lysine-serine-arginine- Tyrosine-lysine-serine) and cleavage peptide (polypeptide sequence: lysine-leucine-2-aminoisobutyric acid-lysine-leucine-2-aminoisobutyric acid-lysine -lysine-leucine-2-aminoisobutyric acid-lysine-leucine-2-aminoisobutyric acid-lysine) combination, in an attempt to increase the targeted toxicity to VEGFR high-expressing cel...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a VEGFR (vascular endothelial growth factor receptor)-targeted cleavage peptide conjugate and application thereof, a polypeptide ligand of a targeted VEGFR is coupled with cleavage peptide KLU to form a dual-function polypeptide conjugate with an anti-tumor effect, and the specific structure is shown in Figure 1. The invention further discloses the binding capacity of the VEGFR-targeted cleavage peptide conjugate to VEGFR on the surface of a vascular endothelial cell and the binding capacity of the cleavage peptide conjugate to the VEGFR on the surface of the vascular endothelial cell. Experiments of cell proliferation, cell apoptosis and the like prove that the split peptide conjugate can effectively inhibit proliferation of malignant liver cancer. According to the present invention, the rabbit liver cancer treatment experiment through the combination of the VEGFR-targeting lysis peptide conjugate and the hepatic artery embolism shows that the polypeptide conjugate can effectively inhibit the proliferation of the in-vivo tumor, and further has significant in-vivo anti-angiogenesis effect; further biological safety evaluation shows that the split peptide conjugate drug has better biocompatibility and does not cause injury to tissues and organs of a body.

Description

technical field [0001] The invention belongs to the field of bioengineering, and relates to a polypeptide drug conjugate, in particular to a split peptide conjugate targeting VEGFR and its anti-liver cancer application. Background technique [0002] Cancer is a major public health problem worldwide. According to the 2020 global cancer data released by the WHO, there will be 4.57 million new cancer cases and more than 3 million deaths in China in 2020. The number of new cancer cases in China ranks first in the world. Liver cancer, represented by hepatocellular carcinoma (HCC), is the fifth most common cancer and the second leading cause of cancer death worldwide. Unlike the surrounding liver parenchyma, liver tumors are preferentially vascularized by the hepatic artery rather than the portal vein. This difference in vascularization makes selective intravascular delivery of drugs, embolic agents, or radiopharmaceuticals promising for effective treatment of HCC. Studies have...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K19/00A61K38/10A61K47/64A61P35/00
CPCC07K7/08C07K7/02A61K47/64A61K38/10A61P35/00C07K2319/00C07K2319/33
Inventor 王冬园熊斌张玉刘家成曾芳黄怡菲
Owner XIEHE HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI & TECH UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products